Epigenetic Effects in Children With Cow's Milk Allergy Treated With Different Formulas
NCT ID: NCT04184700
Last Updated: 2025-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
90 participants
INTERVENTIONAL
2019-12-10
2024-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EHCF + LGG
Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG
EHCF+LGG
Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG
RHF
Extensively hydrolyzed rice formula
RHF
Rice hydrolysed formula
EHWF
Extensively hydrolyzed protein formula
EHWF
extensively hydrolysed whey formula
AAF
Amino acid based formula
AAF
amino acid based formula
SF
Soy formula
SF
Soy formula
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EHCF+LGG
Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG
RHF
Rice hydrolysed formula
SF
Soy formula
EHWF
extensively hydrolysed whey formula
AAF
amino acid based formula
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* congenital cardiac defects,
* active tuberculosis,
* autoimmune diseases,
* immunodeficiency,
* chronic inflammatory bowel diseases,
* celiac disease,
* cystic fibrosis,
* metabolic diseases,
* malignancy,
* chronic pulmonary diseases,
* malformations of the gastrointestinal tract,
* suspected eosinophilic esophagitis or eosinophilic enterocolitis,
* suspected food-protein-induced enterocolitis syndrome,
* suspected cow's milk protein-induced anaphylaxis,
* still on exclusion diet with one of the study formulas or with another dietary regimen because of cow's milk allergy,
* other food allergies.
6 Months
12 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Federico II University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Roberto Berni Canani, MD, PhD
Full professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pediatric Office
Naples, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
28n15
Identifier Type: -
Identifier Source: org_study_id